Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Verucerfont (NBI77860) is an antagonist of corticotropin-releasing factor receptor 1 (CRF1) .
説明 | Verucerfont (NBI77860) is an antagonist of corticotropin-releasing factor receptor 1 (CRF1) . |
ターゲット&IC50 | CRF1:~6.1nM, CRF2:1000 nM, CRF BP:>1000 nM |
In vivo | Verucerfont potently blocked the HPA axis response to the dexamethasone-CRF test, but left alcohol craving unaffected.?Right amygdala responses to negative affective stimuli were significantly attenuated by verucerfont, but responses to alcohol-associated stimuli were increased in some brain regions, including left insula[1]. |
別名 | NBI77860, GSK561679 |
分子量 | 406.48 |
分子式 | C22H26N6O2 |
CAS No. | 885220-61-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 86.7 mg/mL (213.29 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Verucerfont 885220-61-1 GPCR/G Protein CRFR NBI77860 Corticotropin-releasing Factor Receptor Inhibitor NBI-77860 GSK 561679 GSK-561679 NBI 77860 GSK561679 inhibit inhibitor